This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers

This study has been completed.
Information provided by (Responsible Party):
UCB Pharma Identifier:
First received: March 19, 2010
Last updated: September 2, 2011
Last verified: March 2011
The primary objective of this study is to evaluate the effect of certolizumab pegol (CZP) on the quality of sperm obtained from healthy male volunteers.

Condition Intervention Phase
Sperm Quality Biological: Certolizumab pegol Biological: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: A Randomized, Single-center, Double-blind, Placebo-controlled Study to Explore the Effect of a Single Dose of Certolizumab Pegol 400 mg on Semen Quality in Healthy Male Volunteers

Resource links provided by NLM:

Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • Total sperm motility (%) [ Time Frame: baseline to 99 days ]
  • Sperm morphology (%) [ Time Frame: Baseline to 99 days ]

Secondary Outcome Measures:
  • Progressive motility (%) [ Time Frame: Baseline to 99 days ]
  • Non-progressive motility (%) [ Time Frame: Baseline to 99 days ]
  • Sperm vitality (%) [ Time Frame: Baseline to 99 days ]
  • Semen volume (mL) [ Time Frame: Baseline to 99 days ]
  • Sperm count (millions) [ Time Frame: Baseline to 99 days ]
  • Sperm concentration (millions/mL) [ Time Frame: Baseline to 99 days ]

Enrollment: 20
Study Start Date: March 2010
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
0.9% saline
Biological: Placebo
2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
Experimental: Certolizumab pegol
Certolizumab pegol 400 mg
Biological: Certolizumab pegol
400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
Other Name: Cimzia®

Detailed Description:
CZP is a PEGylated humanized Fab' fragment with specificity for human tumor necrosis factor alpha (TNFα). Evidence suggests that modulation of TNFα signaling may affect male spermatogenesis. Therefore, this study will compare semen quality parameters before and after a single 400 mg dose of CZP, or matched placebo.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male volunteers with normal baseline semen quality parameters

Exclusion Criteria:

  • Previous participation in studies involving TNF inhibitors
  • Prior treatment with biologic response modifiers within 5 half-lives
  • History of trauma or surgery to the pelvis/genital area
  • Tests positive for tuberculosis, HIV, Hepatitis B or C
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01091220

Liège, Belgium
Sponsors and Collaborators
UCB Pharma
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
  More Information

Responsible Party: UCB Pharma Identifier: NCT01091220     History of Changes
Other Study ID Numbers: CR0001
2009-015216-17 ( EudraCT Number )
Study First Received: March 19, 2010
Last Updated: September 2, 2011

Keywords provided by UCB Pharma:
certolizumab pegol
healthy male volunteers

Additional relevant MeSH terms:
Certolizumab Pegol
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents processed this record on September 19, 2017